Scarica l'app Stockscreener
68.84
2.65%
1.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$67.06
Aprire:
$66.89
Volume 24 ore:
5.76M
Relative Volume:
2.83
Capitalizzazione di mercato:
$13.26B
Reddito:
$4.08B
Utile/perdita netta:
$32.48M
Rapporto P/E:
36.42
EPS:
1.89
Flusso di cassa netto:
$16.80M
1 W Prestazione:
+0.42%
1M Prestazione:
-3.11%
6M Prestazione:
+10.39%
1 anno Prestazione:
+13.30%
Intervallo 1D:
$66.89
$69.11
Intervallo di 1 settimana:
$66.33
$70.88
Portata 52W:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
68.84 | 13.26B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Co. (NASDAQ:INCY) Stock Position Lowered by Sanctuary Advisors LLC - MarketBeat
Incyte price target raised to $70 from $68 at Wells Fargo - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte (NASDAQ:INCY) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.18 - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Insider Selling: Incyte Co. (NASDAQ:INCY) Insider Sells 650 Shares of Stock - MarketBeat
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock - Investing.com
Incyte (NASDAQ:INCY) Earns Neutral Rating from Analysts at UBS Group - MarketBeat
Orion Portfolio Solutions LLC Purchases New Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Wellington Management Group LLP Has $4.74 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte to Present at Upcoming Investor Conference - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Toronto Dominion Bank Purchases 7,812 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Incyte's SWOT analysis: stock faces patent cliff as pipeline progress unfolds - Investing.com
Incyte (NASDAQ:INCY) Earns Outperform Rating from William Blair - MarketBeat
Vestcor Inc Has $174,000 Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Oppenheimer maintains $82 target on Incyte post-ASH updates - Investing.com
Incyte Co. (NASDAQ:INCY) Stake Boosted by National Bank of Canada FI - MarketBeat
Tri Ri Asset Management Corp Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Continuum Advisory LLC Cuts Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Tri Ri Asset Management Corp Makes New Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals - MSN
Barclays PLC Boosts Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch
Biotech Roundup: 3 Stocks to Watch - Schaeffers Research
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma - Yahoo Finance
Incyte reports positive Phase 3 data for Zynyz for lung cancer - MSN
Incyte (INCY) Stock Drops Amid Market Volatility - GuruFocus.com
Narrow-Moat Incyte's Hematology and Dermatology Platforms Drive Growth - Morningstar
Incyte reports positive Phase 3 data for Zynyz for lung cancer (NASDAQ:INCY) - Seeking Alpha
CURE Media Group announces winners of the 2024 MPN Heroes® Recognition Program - GlobeNewswire Inc.
Janus Henderson Group PLC Has $11.31 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
State Street Corp Sells 300,240 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Quantinno Capital Management LP Has $4.49 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Royal London Asset Management Ltd. Decreases Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte gains amid takeover speculation - MSN
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer - Yahoo Finance
Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Jacobs Levy Equity Management Inc. Trims Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Fmr LLC - MarketBeat
Verition Fund Management LLC Buys Shares of 40,467 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Edgestream Partners L.P. Makes New Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Erste Asset Management GmbH Buys New Shares in Incyte Co. (NASDAQ:INCY) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Incyte Corp Azioni (INCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tray Thomas | Principal Accounting Officer |
Dec 16 '24 |
Sale |
69.31 |
650 |
45,052 |
23,312 |
2.88%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):